Health Secretary Robert F. Kennedy Jr. Overrules FDA to Allow Compounding of Six Peptides

Health Secretary Robert F. Kennedy Jr. has unilaterally issued a new enforcement discretion policy that allows specialty compounding pharmacies to sell six specific peptide drugs, overriding objections from scientists at the Food and Drug Administration (FDA).

The rule, titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” was made available on the Federal Register with a final publication date set for October 30. It states that the Department of Health and Human Services (HHS) will no longer take enforcement action against compounding pharmacies for producing and selling the six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.

Background and FDA Concerns

In 2023, the FDA removed these six peptides from the list of substances allowed for compounding by specialty pharmacies due to safety concerns. FDA scientists maintain that there is insufficient evidence to prove the peptides are effective and warn that they are potentially dangerous.

Rather than formally reversing the 2023 FDA action, the new policy utilizes enforcement discretion. To support the decision, HHS pointed to a July vote by an FDA advisory panel to add the peptides back to the compounding list. However, reports noted that Kennedy had recently appointed eight new members to the 12-member committee, with several appointees having ties to peptide-related businesses, raising conflict-of-interest concerns.

Rationale and Arguments

• Safety and Supply: HHS argues that making the peptides available through domestic compounding pharmacies will deter patients from purchasing research-use-only formulas from foreign manufacturers or the gray and black markets.
• Patient Choice: The policy frames the decision as a way to advance patient freedom while providing a more controlled alternative to illegal versions.
• Lack of Human Studies: HHS stated that existing safety concerns are largely hypothetical or inferential due to a lack of comprehensive human clinical trials demonstrating either benefits or harms.

Reactions and Criticisms

Online peptide sellers and wellness advocates celebrated the announcement on social media and through organizational statements, thanking administration officials for expanding access.

Conversely, critics have raised significant concerns:

• Public Health Risks: The Center for Science in the Public Interest (CSPI) warned that increasing accessibility to unproven substances could lead to mounting reports of harm and disincentivize rigorous pharmaceutical clinical trials.
• Lack of Oversight: Fred Mills of Americans for Safe and Effective Medicines stated that the rule fails to resolve issues regarding untested products and questioned ingredients, potentially worsening mass compounding harms due to reduced regulatory oversight.

Practical Implications and Verification

The policy takes effect according to the Federal Register schedule, altering enforcement priorities rather than the official regulatory approval status of the drugs. Interested individuals can review the official Federal Register notice and HHS policy documents directly online to verify the exact terms of the enforcement discretion policy.